ISB News

Andy Hill CARE Fund Awards $100,000 to ISB Assistant Professor Dr. Wei Wei 

ISB Assistant Professor Dr. Wei Wei

ISB Assistant Professor Dr. Wei Wei was awarded a $100,000 grant by The Andy Hill CARE Fund to study chronic lymphocytic leukemia (CLL), one of the most commonly diagnosed leukemias in the Western world that mainly affects older individuals.

The COVID-19 pandemic has put cancer patients, cancer survivors, and their families at particular risk. To address this problem, the Andy Hill Cancer Research Endowment (CARE) Fund has created a grant program seeking to advance research at the intersection of COVID-19 and cancer. 

ISB Assistant Professor Dr. Wei Wei has been awarded a $100,000 grant to study chronic lymphocytic leukemia (CLL), one of the most commonly diagnosed leukemias in the Western world that mainly affects older individuals. 

“Patients with chronic CLL are among the most vulnerable populations to SARS-CoV-2 infection, and they have a more severe clinical phenotype and a higher fatality rate relative to patients with solid organ tumors,” Wei said. “With the generous support from the Andy Hill CARE Fund, we will leverage biospecimens and data from the COVID-19 Immune Response Study to interrogate CLL-associated dysregulated immune cell functions that have drastic consequences for host protection against SARS-CoV-2 and other viral infections.” 

The research aims to provide an improved understanding of how the altered epigenetic landscape and transcriptional reprogramming in CLL patients influences the activation, differentiation, and function of immune cells upon COVID-19 infection, and how these dysregulated processes lead to a compromised antiviral response. 

“The knowledge obtained from this study holds the promise to inform and improve cancer treatments in leukemia patients at serious risk of secondary infections,” Wei said.

RELATED: A Better Way to Find Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients

Two other cancer researchers also received $100,000 in funding: Dr. Garnet Anderson at Fred Hutchinson Cancer Research Center to assess COVID-19-related cancer care disparities among an aging population, and Dr. Chaitra Ujjani of the University of Washington to examine the efficacy of the SARS-CoV-2 vaccine in CLL patients.

The Andy Hill CARE Fund is a public-private partnership that supports cancer research in Washington state. Past awards to ISB include a $500,000 grant to Wei in 2019, and a $500,000 grant to ISB President and Professor Dr. Jim Heath in December 2017.

Recent Articles

  • ISB President Dr. Jim Heath

    ISB Leading NCI Comprehensive Cancer Center to Study Sequential Targeted Inhibitors and Immunotherapies

    The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.

  • 2022 ISB Virtual Microbiome Series

    2022 ISB Virtual Microbiome Series Announced

    Our multi-day microbiome-themed virtual course and symposium is back for the third year! ISB is hosting a two-day course on October 12 & 13, 2022, followed by a symposium on October 14, 2022 on global perspectives in microbiome research. Both events are virtual and free. The intended audience for these events are graduate students, postdocs, principal investigators, industry scientists, educators, clinicians, or any other variety of microbiome-curious people from across the globe.

  • Bugs vs. Drugs: How Our Microbiomes Can Explain Our Response to Statins

    ISB Assistant Professor Dr. Sean Gibbons talked about the science behind statins in our most recent Research Roundtable virtual presentation. His talk was titled “Bugs vs. Drugs: How Our Unique Gut Microbiomes Shape Our Personalized Responses to Statins.”